Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 14/20 | 0.46 |
| ▸ | KDM1A | O60341 | 6/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19466089 | 1.00 | UGCG (0.46) | UGCGKDM1ACYP3A4 | |
| SCHEMBL19634349 | 0.81 | KDM1A (0.52) | UGCGKDM1A | |
| SCHEMBL18059539 | 0.81 | KDM1A (0.52) | UGCGKDM1A | |
| SCHEMBL16455167 | 0.79 | KDM1A (0.52) | UGCGKDM1ACYP3A4 | |
| SCHEMBL18059520 | 0.77 | KDM1A (0.49) | KDM1ACYP3A4 | |
| SCHEMBL18848473 | 0.77 | KDM1A (0.49) | KDM1ACYP3A4 | |
| SCHEMBL18848618 | 0.77 | KMT2A (0.51) | UGCGKDM1ACYP3A4 | |
| SCHEMBL26148692 | 0.73 | UGCG (0.52) | UGCGCYP3A4 | |
| SCHEMBL16455122 | 0.72 | UGCG (0.51) | UGCGCYP3A4 | |
| SCHEMBL19466153 | 0.71 | KDM1A (0.58) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370346-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20170334873-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9790195-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160257662-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334873-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | UGCG 3745/4885KDM1A 2/4885CYP3A4 4183/4885 |
| US-20160257662-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | UGCG 4101/4885KDM1A 2/4885CYP3A4 3948/4885 |
| US-10370346-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | UGCG 3745/4885KDM1A 2/4885CYP3A4 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.